Navigation Links
Ranbaxy gets US FDA approval for Lisinopril

Ranbaxy Pharmaceuticals Inc (RPI) has received a tentative approval from the US FDA for Lisinopril tablets. Lisinopril is recommended for hypertension, either alone for initial therapy or with other classes of anti-hypertenive agents. It is also used as adjunctive therapy in the management of heart failure and patients who do not respond to diuretics. //

However it expects to launch the product only in June 2002, when the original patent expires on the drug, Zestril. Zestril is a registered trademark of Astra Zeneca UK Ltd. A wholly-owned subsidiary of Ranbaxy Laboratories Ltd, RPI expects to be able to access retail pharmacy outlets, wholesalers, hospitals and generic distributors in the US, only post - June 2002.

Sales in 2000 for Lisinopril touched $ 1.2 billion. It is sold under two brands in the US market , of which Zestril alone sold $ 0.66 billion in 2000. The tentative approval has been given for a single entity form of Lisinopril. An Abbreviated New Drug Application (ANDA) submission by Ranbaxy, for Lisinopril and Hydrochlorithizide is still outstanding and pending approval from the US FDA.

The tentative US FDA approval has been given for Lisinopril tablets USP 2.5 mg, 5 mg, 10 mg 20 mg and 40 mg. Based on kinetic studies, it has been deemed to be a bio-equivalent and therapeutically equivalent to Zestril tablets. The tentatively approved formulation is the result of R&D efforts that focussed on the Active Pharmaceutical Ingredient and the bio-equivalent formulation, both of which were developed in-house.


'"/>




Page: 1

Related medicine news :

1. Ranbaxy joins hand with Cipla to co-market ciprofloxacin
2. Ranbaxy Labs Entry Into Anti-Acne Market
3. Ranbaxy trying to make inroads in herbal drugs market
4. Lamivudine Manufactured By Ranbaxy gets the nod from the US FDA
5. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
6. Ranbaxy opens Drug discovery centre in Gurgaon
7. Ranbaxy Laboratories All Set To Export Bird Flu Vaccines
8. SRL Ranbaxy offers quicker bird flu diagnostic test
9. Diagnostic Test Launched by Ranbaxy for En Masse Screening of Bird Flu
10. Ranbaxy Launches Once-a-day Inhaler For Asthma Patients
11. Ranbaxy Expands By Acquiring A Generic Company In Belgium
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/29/2016)... ... April 29, 2016 , ... ... Footwear Foundation, the national charitable foundation serving the footwear industry, has broken all ... representing more than 130 companies across 23 states during the months of April ...
(Date:4/29/2016)... Georgia (PRWEB) , ... April 29, 2016 , ... On ... rural hospitals across the Southeast, celebrated the signature of Gov. Nathan Deal on SB ... Rep. Geoff Duncan (R - Cumming), offers a 70% tax credit to individuals and ...
(Date:4/29/2016)... STAMFORD, CONNECTICUT (PRWEB) , ... April 29, 2016 , ... ... 5K Run/Walk” at Cove Island Park on Sunday, with sunny skies, a light breeze ... event, raising nearly $33,000. , The 5k Run and Walk and 1-mile ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Wharton School of ... Grand Prize of the 2016 Wharton Business Plan Competition —as well as ... Award, and the Committee Award for Most ‘Wow Factor,’ making them the first ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Melanoma is the deadliest type of skin cancer. ... for the majority of skin cancer deaths. More than 10,000 people are expected to die ... diagnosis is 62, it is the one of the most commonly diagnosed cancers in young ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... Dr. ... und Stephen Schmidt werden Teil ... ein führender Anbieter cloudbasierter Softwarelösungen für den ... neue Führungskräfte zum Team Sicherheit und Pharmakovigilanz ... Erfahrungen mitbringen.  Dies wird die Geschäftseinheit Sicherheit ...
(Date:4/28/2016)... , April 28, 2016 Oramed Pharmaceuticals ... clinical-stage pharmaceutical company focused on the development of oral drug ... the upcoming PIONEERS 2016 conference, presented by Joseph Gunnar ... in New York . Nadav Kidron ... the conference. Presentation Details:   ...
(Date:4/27/2016)...  Hologic, Inc. (Nasdaq: HOLX ) ... fiscal second quarter ended March 26, 2016.  GAAP ... 41.2%, and non-GAAP diluted EPS of $0.47 increased ... a reported basis, and 6.3% on a constant ... good quarter, highlighted by 14.6% growth in non-GAAP ...
Breaking Medicine Technology: